WO2007104557A3 - Novel heterocyclic nf-kb inhibitors - Google Patents

Novel heterocyclic nf-kb inhibitors Download PDF

Info

Publication number
WO2007104557A3
WO2007104557A3 PCT/EP2007/002265 EP2007002265W WO2007104557A3 WO 2007104557 A3 WO2007104557 A3 WO 2007104557A3 EP 2007002265 W EP2007002265 W EP 2007002265W WO 2007104557 A3 WO2007104557 A3 WO 2007104557A3
Authority
WO
WIPO (PCT)
Prior art keywords
cycloalkyl
inhibitors
novel heterocyclic
hydroxyalkylamino
haloalkyloxy
Prior art date
Application number
PCT/EP2007/002265
Other languages
French (fr)
Other versions
WO2007104557A2 (en
Inventor
Johann Leban
Harald Schmitt
Kristina Wolf
Stefano Pegoraro
Andreas Wuzik
Rolf Krauss
Original Assignee
4Sc Ag
Johann Leban
Harald Schmitt
Kristina Wolf
Stefano Pegoraro
Andreas Wuzik
Rolf Krauss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2006/002396 external-priority patent/WO2007016979A2/en
Priority claimed from US11/375,259 external-priority patent/US7601745B2/en
Priority to MX2008011696A priority Critical patent/MX2008011696A/en
Priority to CA002646223A priority patent/CA2646223A1/en
Priority to EP07711946A priority patent/EP1994017A2/en
Priority to JP2008558718A priority patent/JP2009529555A/en
Application filed by 4Sc Ag, Johann Leban, Harald Schmitt, Kristina Wolf, Stefano Pegoraro, Andreas Wuzik, Rolf Krauss filed Critical 4Sc Ag
Priority to EA200801838A priority patent/EA200801838A1/en
Priority to BRPI0709595-3A priority patent/BRPI0709595A2/en
Priority to AU2007224659A priority patent/AU2007224659A1/en
Publication of WO2007104557A2 publication Critical patent/WO2007104557A2/en
Publication of WO2007104557A3 publication Critical patent/WO2007104557A3/en
Priority to IL193981A priority patent/IL193981A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds of the general formula (Ih) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof, (Ih) wherein A is NR2, S or O; R3a is H, OH, SH, NH2, -C(NR7)NR7'R8, -(CH2)paryl, -(CH2)PNR7R8, -C(O)NR7R8, -N=CR7R8, -NR7C(O)R8, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, alkoxy, alkylamino, hydroxyalkylamino, halogen, aryl, or heteroaryl; R3 is H, -C(0)NRaRb, halogen, alkyl, haloalkyl, aryl, heteroaryl, OH, SH, NR4' OR5', NH2, hydroxyalkylamino, alkylamino, alkoxy, cycloalkyl, hetero- cycloalkyl, hydroxyalkyl, or haloalkyloxy; X is NR2', O, or S; Z is N or CR2'.
PCT/EP2007/002265 2006-03-15 2007-03-14 Novel heterocyclic nf-kb inhibitors WO2007104557A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2007224659A AU2007224659A1 (en) 2006-03-15 2007-03-14 Novel heterocyclic NF-KB inhibitors
BRPI0709595-3A BRPI0709595A2 (en) 2006-03-15 2007-03-14 heterocyclic nf-kapab inhibitors
CA002646223A CA2646223A1 (en) 2006-03-15 2007-03-14 Novel heterocyclic nf-kb inhibitors
EP07711946A EP1994017A2 (en) 2006-03-15 2007-03-14 Novel heterocyclic nf-kb inhibitors
JP2008558718A JP2009529555A (en) 2006-03-15 2007-03-14 Novel heterocyclic NF-κB inhibitor
MX2008011696A MX2008011696A (en) 2006-03-15 2007-03-14 Novel heterocyclic nf-kb inhibitors.
EA200801838A EA200801838A1 (en) 2006-03-15 2007-03-14 NEW HETEROCYCLIC INHIBITORS NF-kB
IL193981A IL193981A0 (en) 2006-03-15 2008-09-09 Novel heterocyclic nf-kb inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2006/002396 WO2007016979A2 (en) 2005-07-29 2006-03-15 NOVEL HETEROCYCLIC NF-κB INHIBITORS
US11/375,259 US7601745B2 (en) 2004-09-27 2006-03-15 Heterocyclic NF-kB inhibitors
US11/375,259 2006-03-15
EPPCT/EP2006/002396 2006-03-15

Publications (2)

Publication Number Publication Date
WO2007104557A2 WO2007104557A2 (en) 2007-09-20
WO2007104557A3 true WO2007104557A3 (en) 2008-05-22

Family

ID=38461965

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/002265 WO2007104557A2 (en) 2006-03-15 2007-03-14 Novel heterocyclic nf-kb inhibitors

Country Status (3)

Country Link
EP (1) EP1994017A2 (en)
CN (1) CN101405278A (en)
WO (1) WO2007104557A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007115805A2 (en) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
JP2010522724A (en) * 2007-03-27 2010-07-08 ４エスツェー アクチェンゲゼルシャフト Pharmaceutical composition containing cytokine
CA2699817A1 (en) * 2007-09-19 2009-03-26 4Sc Ag Benzimidazole nf- kappab inhibitors
DE102007047735A1 (en) * 2007-10-05 2009-04-09 Merck Patent Gmbh thiazole
PL2206707T3 (en) * 2007-10-24 2015-01-30 Astellas Pharma Inc Azolecarboxamide compound or salt thereof
JP2011518109A (en) * 2007-11-30 2011-06-23 ビオタ サイエンティフィック マネージメント ピーティーワイ リミテッド Tetrahydro-isoquinoline PPAT inhibitors as antibacterial agents
EP2225250A2 (en) 2007-11-30 2010-09-08 Biota Scientific Management Pty Ltd Bicyclic ppat inhibitors as antibacterial agents
AU2008340434B2 (en) * 2007-12-21 2014-02-06 Boehringer Ingelheim Animal Health USA Inc. The use of 6-halogeno-[1,2,4]-triazolo-[1,5-a]-pyrimidine compounds for combating pests in and on animals
US8546575B2 (en) * 2008-05-05 2013-10-01 Merck Patent Gmbh NIP thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydroge-nase-1
US8716312B2 (en) * 2008-11-19 2014-05-06 Merck Sharp & Dohme Corporation Inhibitors of diacylglycerol acyltransferase
KR101051077B1 (en) * 2008-12-05 2011-07-21 한국화학연구원 2-piperazino-4,5-disubstituted-1,3-thiazole derivatives, preparation method thereof and therapeutic agent for inflammation-related diseases caused by spC receptor activity containing the same as an active ingredient
AR074830A1 (en) 2008-12-19 2011-02-16 Cephalon Inc PIRROLOTRIAZINAS AS ALK AND JAK2 INHIBITORS
FR2969611B1 (en) * 2010-12-28 2013-02-08 Sanofi Aventis NOVEL THIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS AKT PHOSPHORYLATION INHIBITORS (PKB)
GB201401886D0 (en) 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
CN104356127B (en) * 2014-11-13 2017-06-16 重庆理工大学 Containing the double heterocyclic amides of N and its application as immunodepressant
CN109988121B (en) * 2019-04-28 2023-01-03 梯尔希（南京）药物研发有限公司 Preparation method of acotiamide derivative
WO2022112205A1 (en) * 2020-11-25 2022-06-02 F. Hoffmann-La Roche Ag Aromatic bridged ring amide derivatives for the treatment and prophylaxis of hepatitis b virus infection
CN114712503B (en) * 2021-10-09 2023-05-26 浙江大学 Application of c-Abl inhibitor in preparation of medicament for preventing and/or treating amyotrophic lateral sclerosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343893A1 (en) * 1988-05-24 1989-11-29 Pfizer Inc. Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
WO2004058751A1 (en) * 2002-12-24 2004-07-15 Metris Therapeutics Limited Piperidinyl-thiazole carboxamide derivatives for altering vascular tone
WO2005079791A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
WO2006032322A1 (en) * 2004-09-20 2006-03-30 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343893A1 (en) * 1988-05-24 1989-11-29 Pfizer Inc. Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
WO2004058751A1 (en) * 2002-12-24 2004-07-15 Metris Therapeutics Limited Piperidinyl-thiazole carboxamide derivatives for altering vascular tone
WO2005079791A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
WO2006032322A1 (en) * 2004-09-20 2006-03-30 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS

Also Published As

Publication number Publication date
EP1994017A2 (en) 2008-11-26
WO2007104557A2 (en) 2007-09-20
CN101405278A (en) 2009-04-08

Similar Documents

Publication Publication Date Title
WO2007104557A3 (en) Novel heterocyclic nf-kb inhibitors
WO2007016979A3 (en) NOVEL HETEROCYCLIC NF-κB INHIBITORS
NZ599040A (en) 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases
MX2009010491A (en) 5-membered heterocyclic derivative and use thereof for medical purposes.
WO2010117323A8 (en) Isoxazol-3(2h)-one analogs as therapeutic agents
NZ627036A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
WO2008038051A3 (en) Use of ion channel modulators in the prophylaxis and treatment of inflammatory and immunological diseases
PE20130188A1 (en) HETEROAROMATIC PYRROLIDINONES FUSED AS SYK INHIBITORS
JP2012511588A5 (en)
WO2008114819A1 (en) Novel adenine compound
MX2012015023A (en) Novel nicotinamide derivatives or salts thereof.
WO2012003405A4 (en) Sgc stimulators
HK1126756A1 (en) Process for preparation of hiv protease inhibitors
WO2007137874A3 (en) Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
WO2007083090A3 (en) Process for the preparation of uracil derivatives
MY172860A (en) Dimethyl-benzoic acid compounds
MX344529B (en) 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives.
WO2008062379A3 (en) 4- (2-oxo-oxazolidin-3yl)-phenoxymethyle derivativeas as antibacterials
MY146537A (en) Triazolone derivative
PH12015500009B1 (en) Phenoxyethyl piperidine compounds
MX2011011303A (en) Isoxazole derivatives.
HK1110855A1 (en) Dihydropyridine derivatives
EA200801838A1 (en) NEW HETEROCYCLIC INHIBITORS NF-kB
TW200621241A (en) Process for the preparation of isothiazole derivatives
JP2009523141A5 (en)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 193981

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/011696

Country of ref document: MX

Ref document number: 7729/DELNP/2008

Country of ref document: IN

Ref document number: 1020087022353

Country of ref document: KR

Ref document number: 2007711946

Country of ref document: EP

Ref document number: 200801838

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2007224659

Country of ref document: AU

Ref document number: 2646223

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 200780009233.6

Country of ref document: CN

Ref document number: 2008558718

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2007224659

Country of ref document: AU

Date of ref document: 20070314

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 571978

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: a200812167

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0709595

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080915